This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrialfibrillation ablation, Musat et al. recommend shortening the blanking period from three months to one. Lead author Jonathan M. also emphasize the importance of continuous monitoring.
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the HeartRhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. EDT, in Rhythm Theater #2.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation.
The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources.
male with pertinent past medical history including Atrialfibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. He was noted to have irregular heartrhythm with rates 120-170s.
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at HeartRhythm 2024 Highlight Pulsed Field Ablation Developments for AtrialFibrillation Treatment 8. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment.
The first procedures were performed by Dr. David Newton , Clinical Cardiac Electrophysiologist at Memorial Health University Physicians Heart Care and Dr. Andrea Natale , Executive Medical Director at T exas Cardiac Arrhythmia Institute, St.
During its Annual Conference, HRS 2024, the HeartRhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). Lucas Boersma , electrophysiologist, St.
The VARIPULSE Platform is designed to enable pulmonary vein isolation with the versatility of a catheter loop, a simple generator user interface, and a mapping system that provides an intuitive, reproducible workflow with real-time visualization, contact indicator, and PF tagging mechanisms. Int J Stroke. 2021 Feb;16(2):217-221.
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. Our mission to combat complex heartrhythm diseases relies on optimizing interoperability.
The PulseSelect PFA system was engineered with differentiated safety features and provides rapid, effective pulmonary vein isolation (PVI) through consistent and predictable energy delivery and catheter maneuverability. Mortality trends in patients diagnosed with first atrialfibrillation: a 21-year community-based study.
tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrialfibrillation (AFib). The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) the method of destroying tissue causing a patient's AFib in 99.1%
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrialfibrillation ( AF ) using pulsed field ablation (PFA). He was not compensated for any media work.
Brugada Syndrome: Diagnosis and Risk Stratification Hello friends, this is the modified version of my talk at Indian HeartRhythm Society Conference, New Delhi, 2023, on Brugada Syndrome. Atrial arrhythmias may occur in about 10% of those with Brugada syndrome and atrialfibrillation is the commonest sustained atrial arrhythmia.
MANIFEST-17K provides confidence that, unlike conventional thermal ablation, PFA with the pentaspline catheter does not cause the most feared complication of AF ablation—esophageal damage—nor does it cause pulmonary vein stenosis or persistent injury to the diaphragm,” says senior author Vivek Reddy, MD , The Leona M. and Harry B.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content